440 related articles for article (PubMed ID: 23622131)
21. RAS oncogenic signal upregulates EZH2 in pancreatic cancer.
Fujii S; Fukamachi K; Tsuda H; Ito K; Ito Y; Ochiai A
Biochem Biophys Res Commun; 2012 Jan; 417(3):1074-9. PubMed ID: 22222375
[TBL] [Abstract][Full Text] [Related]
22. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
23. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.
Duan YF; Li DF; Liu YH; Mei P; Qin YX; Li LF; Lin QX; Li ZJ
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):204-9. PubMed ID: 23558076
[TBL] [Abstract][Full Text] [Related]
24. Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation.
Mills LD; Zhang Y; Marler RJ; Herreros-Villanueva M; Zhang L; Almada LL; Couch F; Wetmore C; Pasca di Magliano M; Fernandez-Zapico ME
J Biol Chem; 2013 Apr; 288(17):11786-94. PubMed ID: 23482563
[TBL] [Abstract][Full Text] [Related]
25. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.
Yu S; Lu Z; Liu C; Meng Y; Ma Y; Zhao W; Liu J; Yu J; Chen J
Cancer Res; 2010 Jul; 70(14):6015-25. PubMed ID: 20610624
[TBL] [Abstract][Full Text] [Related]
26. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
27. Aldh1b1 expression defines progenitor cells in the adult pancreas and is required for Kras-induced pancreatic cancer.
Mameishvili E; Serafimidis I; Iwaszkiewicz S; Lesche M; Reinhardt S; Bölicke N; Büttner M; Stellas D; Papadimitropoulou A; Szabolcs M; Anastassiadis K; Dahl A; Theis F; Efstratiadis A; Gavalas A
Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20679-20688. PubMed ID: 31548432
[TBL] [Abstract][Full Text] [Related]
28. GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.
Bang D; Wilson W; Ryan M; Yeh JJ; Baldwin AS
Cancer Discov; 2013 Jun; 3(6):690-703. PubMed ID: 23547054
[TBL] [Abstract][Full Text] [Related]
29. Challenges in Ras therapeutics in pancreatic cancer.
Choi M; Bien H; Mofunanya A; Powers S
Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic KRAS signalling in pancreatic cancer.
Eser S; Schnieke A; Schneider G; Saur D
Br J Cancer; 2014 Aug; 111(5):817-22. PubMed ID: 24755884
[TBL] [Abstract][Full Text] [Related]
31. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
32. In vivo serial selection of human pancreatic cancer cells in orthotopic mouse models produces high metastatic variants irrespective of Kras status.
Metildi CA; Kaushal S; Hoffman RM; Bouvet M
J Surg Res; 2013 Sep; 184(1):290-8. PubMed ID: 23590868
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic KRAS promotes malignant brain tumors in zebrafish.
Ju B; Chen W; Orr BA; Spitsbergen JM; Jia S; Eden CJ; Henson HE; Taylor MR
Mol Cancer; 2015 Feb; 14(1):18. PubMed ID: 25644510
[TBL] [Abstract][Full Text] [Related]
34. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.
Yuan F; Shi M; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Int J Biol Sci; 2014; 10(9):957-65. PubMed ID: 25210493
[TBL] [Abstract][Full Text] [Related]
35. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.
Rachagani S; Senapati S; Chakraborty S; Ponnusamy MP; Kumar S; Smith LM; Jain M; Batra SK
Br J Cancer; 2011 Mar; 104(6):1038-48. PubMed ID: 21364589
[TBL] [Abstract][Full Text] [Related]
36. An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer.
Kent OA; Sandí MJ; Burston HE; Brown KR; Rottapel R
Oncotarget; 2017 Jan; 8(3):4484-4500. PubMed ID: 27835861
[TBL] [Abstract][Full Text] [Related]
37. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras.
Carrière C; Young AL; Gunn JR; Longnecker DS; Korc M
Biochem Biophys Res Commun; 2009 May; 382(3):561-5. PubMed ID: 19292977
[TBL] [Abstract][Full Text] [Related]
38. Mouse models of pancreatic cancer.
Herreros-Villanueva M; Hijona E; Cosme A; Bujanda L
World J Gastroenterol; 2012 Mar; 18(12):1286-94. PubMed ID: 22493542
[TBL] [Abstract][Full Text] [Related]
39. [Kras oncogene and pancreatic cancer: thirty years after].
Bournet B; Dufresne M; Selves J; Torrisani J; Cordelier P; Buscail L
Med Sci (Paris); 2013 Nov; 29(11):991-7. PubMed ID: 24280502
[TBL] [Abstract][Full Text] [Related]
40. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia.
De La O JP; Emerson LL; Goodman JL; Froebe SC; Illum BE; Curtis AB; Murtaugh LC
Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18907-12. PubMed ID: 19028876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
